Anika Therapeutics Inc. (ANIK) vs Lifecore Biomedical, Inc. (LFCR)

Anika Therapeutics Inc. and Lifecore Biomedical, Inc. are both Drug Manufacturers Specialty & Generic companies. Anika Therapeutics Inc. and Lifecore Biomedical, Inc. are of similar size ($258.7M and $242.6M). Anika Therapeutics Inc. grew revenue faster over the last twelve months: 5.33% against −18.2%. Anika Therapeutics Inc. has the higher net margin (−3.14% vs −65.9%) and the lower return on invested capital (−3.24% vs 0.00%). Across the 17 metrics below, Anika Therapeutics Inc. leads on 10 and Lifecore Biomedical, Inc. on 7.

Valuation

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 2.13 2.13 2.08
P/B 1.88 n/m 1.79
Price to free cash flow 458.01 36.27 16.29
EV/EBITDA 476.54 n/m 12.22
EV/Sales 2.02 3.56 2.87
Earnings yield (1.35%) (31.14%) (15.94%)
Free cash flow yield 0.22% 2.76% 0.00%

Profitability

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
Gross margin 62.16% 27.38% 53.51%
Operating margin (4.24%) (5.33%) 0.00%
Net margin (3.14%) (65.91%) (2.45%)
Free cash flow margin 0.47% 9.86% 0.00%
Return on equity (2.66%) 178.69% (0.80%)
Return on assets (2.04%) (32.36%) (1.67%)
Return on invested capital (3.24%) 0.00% 0.00%

Growth

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 5.33% (18.22%) 5.22%
EPS growth (last fiscal year) 80.16% (487.55%) 42.91%
Revenue growth, 5-year CAGR (2.86%) (4.24%) 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.04
Current ratio 4.48 3.84 2.41
Net debt to EBITDA 10.80 (15.59) 1.01

Dividend

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric ANIK LFCR Drug Manufacturers Specialty & Generic median
Market cap 258.69m 242.59m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack